Trump highlights ibogaine research in executive order

Trump boosts ibogaine research with executive order

President Donald Trump has reignited interest in ibogaine, a psychedelic compound, by signing an executive order in April that directs federal agencies to expedite research into psychedelic treatments, according to USA TODAY. This order specifically highlights ibogaine and allocates substantial federal funding to support its study. Following this directive, the Food and Drug Administration (FDA) initiated its first U.S.-based trials of an ibogaine-derived drug.

What the executive order entails

The executive order, signed in April, aims to accelerate research into psychedelic substances, with ibogaine receiving particular attention. Trump announced on Truth Social that the University of Miami has gifted the federal government its original 1994 Ibogaine Investigational New Drug application. This move is intended to provide direct access to foundational FDA authorization, potentially speeding up the development of ibogaine as a medical treatment in the United States.

What is ibogaine?

Ibogaine is a psychoactive substance derived from a Central African shrub, known for its potential in treating substance use disorders. Joseph Barsuglia, a psychologist with extensive experience studying ibogaine, notes that its most notable benefit is its ability to halt opioid withdrawal and eliminate cravings, often after just one session. This effect was first discovered in 1962 by Howard Lotsof, who found that ibogaine unexpectedly alleviated his heroin cravings.

How ibogaine works

The exact mechanism of ibogaine is not fully understood, but it is known to influence the brain's reward and pleasure systems. According to Barsuglia, ibogaine triggers the release of a natural growth factor and modulates neural pathways associated with addiction, helping restore healthy dopamine function. Unlike methadone or suboxone, which require daily dosing, ibogaine appears to repair the brain circuitry damaged by addiction.

Regulatory context and future prospects

Ibogaine is currently classified as a Schedule 1 drug in the United States, indicating no accepted medical use and a high potential for abuse. This classification has hindered its approval, partly due to the lack of financial incentives for pharmaceutical companies to conduct costly FDA-approved trials. However, recent legislative actions in states like Mississippi, Oklahoma, and Tennessee, along with the federal executive order, suggest a shift towards increased research and potential regulatory changes.

Why it matters

The renewed focus on ibogaine research could pave the way for new treatments for opioid addiction, a pressing public health issue. With the support of federal funding and the initiation of FDA trials, ibogaine might eventually become a viable option for those struggling with addiction, offering a novel approach that differs from existing treatments.

Ibogaine's potential to transform addiction treatment underscores the importance of continued research and regulatory exploration.